$MRKR
Marker Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000141057824001978 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $1.926M
YoY Change 647.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $854.7K
YoY Change -39.38%
% of Gross Profit
Research & Development $3.471M
YoY Change 69.74%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.326M
YoY Change 25.11%
Operating Profit -$2.400M
YoY Change -25.01%
Interest Expense $91.68K
YoY Change -58.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.308M
YoY Change -22.54%
Income Tax
% Of Pretax Income
Net Earnings -$2.308M
YoY Change -22.59%
Net Earnings / Revenue -119.84%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.26
COMMON SHARES
Basic Shares Outstanding 8.923M 8.923M
Diluted Shares Outstanding 8.923M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.000M
YoY Change -48.49%
Cash & Equivalents $9.000M
Short-Term Investments
Other Short-Term Assets $1.166M
YoY Change -39.57%
Inventory
Prepaid Expenses $1.166M
Receivables
Other Receivables $744.4K
Total Short-Term Assets $10.91M
YoY Change -44.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $10.91M
Total Long-Term Assets $0.00
Total Assets $10.91M
YoY Change -44.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.904M
YoY Change 63.43%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.461M
YoY Change 24.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.461M
Total Long-Term Liabilities $0.00
Total Liabilities $3.461M
YoY Change 24.51%
SHAREHOLDERS EQUITY
Retained Earnings -$443.2M
YoY Change 2.24%
Common Stock $8.923K
YoY Change 0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.450M
YoY Change
Total Liabilities & Shareholders Equity $10.91M
YoY Change -44.01%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.308M
YoY Change -22.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $1.198M
YoY Change -205.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.700K
YoY Change -99.65%
NET CHANGE
Cash From Operating Activities 1.198M
Cash From Investing Activities
Cash From Financing Activities 1.700K
Net Change In Cash 1.199M
YoY Change -284.49%
FREE CASH FLOW
Cash From Operating Activities $1.198M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
dei Entity Central Index Key
EntityCentralIndexKey
0001094038
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58501
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37939
dei Entity Registrant Name
EntityRegistrantName
MARKER THERAPEUTICS, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4497941
dei Entity Address Address Line1
EntityAddressAddressLine1
2450 Holcombe Blvd, Suite BCM-A, MS: BCM251
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77021
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
400-6400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MRKR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8923490
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8999664
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15111450
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1166274
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
988126
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
744410
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1027815
CY2024Q3 us-gaap Assets Current
AssetsCurrent
10910348
CY2023Q4 us-gaap Assets Current
AssetsCurrent
17127391
CY2024Q3 us-gaap Assets
Assets
10910348
CY2023Q4 us-gaap Assets
Assets
17127391
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2557335
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1745193
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
903438
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1329655
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3460773
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3074848
CY2024Q3 us-gaap Liabilities
Liabilities
3460773
CY2023Q4 us-gaap Liabilities
Liabilities
3074848
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8900000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8900000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8900000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8900000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8923
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8891
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
450620206
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
450329515
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-443179554
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436285863
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7449575
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
14052543
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10910348
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17127391
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1926020
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
257606
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4339317
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2254601
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3471216
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2044980
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8381661
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7799472
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
854677
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1412672
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3214611
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6098716
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4325893
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3457652
us-gaap Operating Expenses
OperatingExpenses
11596272
us-gaap Operating Expenses
OperatingExpenses
13898188
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2399873
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3200046
us-gaap Operating Income Loss
OperatingIncomeLoss
-7256955
us-gaap Operating Income Loss
OperatingIncomeLoss
-11643587
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
91681
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
218085
us-gaap Investment Income Interest
InvestmentIncomeInterest
363264
us-gaap Investment Income Interest
InvestmentIncomeInterest
337819
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2308192
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2981961
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6893691
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11305768
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-2922406
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
8794426
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
5872020
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2308192
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2981961
us-gaap Net Income Loss
NetIncomeLoss
-6893691
us-gaap Net Income Loss
NetIncomeLoss
-5433748
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.26
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.26
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.34
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.34
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.77
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.77
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.29
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.29
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.67
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.66
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8923170
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8825881
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8914487
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8782340
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8923170
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8825881
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8914487
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8834512
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9702764
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1701
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
53302
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2308192
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7449575
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
14052543
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36902
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58501
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
195320
us-gaap Net Income Loss
NetIncomeLoss
-6893691
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7449575
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19034752
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84604
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
394667
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
175041
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2981961
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
16707103
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19601037
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1014640
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85342
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1439832
us-gaap Net Income Loss
NetIncomeLoss
-5433748
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
16707103
us-gaap Profit Loss
ProfitLoss
-6893691
us-gaap Profit Loss
ProfitLoss
-5433748
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
5872020
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6893691
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-11305768
us-gaap Share Based Compensation
ShareBasedCompensation
195320
us-gaap Share Based Compensation
ShareBasedCompensation
714899
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
178148
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
80116
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-283405
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-2318691
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-426217
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
367915
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
812142
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-159567
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
107530
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6207189
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8036416
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-6035961
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6207189
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14072377
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
18664122
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18664122
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36902
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1014640
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58501
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
85342
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95403
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1099982
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6111786
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5691727
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15111450
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11782172
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8999664
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17473899
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1: NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi tumor associated antigen (multiTAA”)-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Agreement with Cell Ready</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC (“Cell Ready”) pursuant to a Purchase Agreement (the “Cell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Company’s board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Company’s two manufacturing facilities in Houston, Texas (the “Manufacturing Facilities”), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Company’s Master Services Agreement for Product Supply (the “MSA”), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the “Purchased Assets”). Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of the Company’s former employees in its manufacturing, development, quality, and regulatory affairs functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Company’s operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification (“ASC”) 205-20 – Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the “MSA”) with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel’s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company’s expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organizational Changes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these costs were completed in July of 2023. Effective May 1, 2023, the Company’s board of directors appointed Dr. Juan Vera as the Company’s President and Chief Executive Officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC (“Danforth”) and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Dr. Vera was appointed as the Company’s Principal Financial and Accounting Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the “Reverse Stock Split”) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p>
CY2023Q2 us-gaap Severance Costs1
SeveranceCosts1
900000
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 2: BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Company’s annual report on Form 10-K filed on March 26, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain amounts presented in prior periods have been reclassified to conform to the current period presentation.</p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000000.0
CY2021Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
13100000
mrkr Funds Received From Cprit Grant
FundsReceivedFromCpritGrant
9700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p>
CY2024Q3 mrkr Cash At Financial Institutions
CashAtFinancialInstitutions
4100000
CY2024Q3 us-gaap Us Government Agencies Securities At Carrying Value
USGovernmentAgenciesSecuritiesAtCarryingValue
4900000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000000.0
CY2023Q4 mrkr Cash At Financial Institutions
CashAtFinancialInstitutions
1400000
CY2023Q4 us-gaap Us Government Agencies Securities At Carrying Value
USGovernmentAgenciesSecuritiesAtCarryingValue
13700000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15100000
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2308192
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2981961
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6893691
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11305768
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
5872020
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2308192
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2981961
us-gaap Net Income Loss
NetIncomeLoss
-6893691
us-gaap Net Income Loss
NetIncomeLoss
-5433748
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8923170
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8825881
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8914487
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8782340
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8923170
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8825881
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8914487
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8834512
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.26
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.26
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.34
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.34
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.77
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.77
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.29
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.67
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.66
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
596000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2648000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
596000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2596000
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
4316641
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
7239048
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-2922406
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1904000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
961000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
57000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
359000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
303000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
903000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1330000
CY2024Q3 mrkr Tax Fees Payable
TaxFeesPayable
52000
CY2023Q4 mrkr Tax Fees Payable
TaxFeesPayable
219000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
204000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
205000
CY2024Q3 mrkr Accounts Payable And Accrued Liabilities Including Related Party Payable Current
AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent
3461000
CY2023Q4 mrkr Accounts Payable And Accrued Liabilities Including Related Party Payable Current
AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent
3075000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23892
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2024Q3 mrkr Stock Compensation In Continuing Operations
StockCompensationInContinuingOperations
53000
CY2023Q3 mrkr Stock Compensation In Continuing Operations
StockCompensationInContinuingOperations
175000
mrkr Stock Compensation In Continuing Operations
StockCompensationInContinuingOperations
195000
mrkr Stock Compensation In Continuing Operations
StockCompensationInContinuingOperations
715000
mrkr Stock Compensation In Discontinued Operations
StockCompensationInDiscontinuedOperations
725000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
175000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
195000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1440000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1235000
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
368000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3077000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
658000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001978-index-headers.html Edgar Link pending
0001410578-24-001978-index.html Edgar Link pending
0001410578-24-001978.txt Edgar Link pending
0001410578-24-001978-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrkr-20240930.xsd Edgar Link pending
mrkr-20240930x10q.htm Edgar Link pending
mrkr-20240930x10q001.jpg Edgar Link pending
mrkr-20240930x10q002.jpg Edgar Link pending
mrkr-20240930x10q003.jpg Edgar Link pending
mrkr-20240930xex31d1.htm Edgar Link pending
mrkr-20240930xex31d2.htm Edgar Link pending
mrkr-20240930xex32d1.htm Edgar Link pending
mrkr-20240930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
mrkr-20240930_cal.xml Edgar Link unprocessable
mrkr-20240930_def.xml Edgar Link unprocessable
mrkr-20240930_lab.xml Edgar Link unprocessable
mrkr-20240930_pre.xml Edgar Link unprocessable
mrkr-20240930x10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable